Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Measles, Mumps, Rubella and Varicella · 1 trial · 5 indications
Percentage of participants who had a concentration of ≥ 300 mIU/mL in the enzyme-linked immunosorbent assay (ELISA) or ≥ 120 mIU/mL in the neutralization when the ELISA concentration was less than 300 mIU/mL - for measles; ≥ 500 U/mL (ELISA) or ≥ 60 (1/dil) in the neutralization assay when the ELISA concentration was less than 500 mIU/mL - for mumps; ≥ 10 IU/mL (ELISA) - for Rubella; and ≥ 300 mIU/mL (ELISA) or ≥ 4 (1/dil) Fluorescent antibody to membrane antigen (FAMA) when the ELISA concentration was less than 300 mIU/mL - for varicella.
| Arm | Type | Description |
|---|---|---|
| Menactra® at 9 and 12 Months | EXPERIMENTAL | Participants will received Menactra® vaccination at 9 and 12 months of age. |
| Menactra® at 9 Months and Menactra® + MMRV at 12 Months | EXPERIMENTAL | Participants will receive Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV) vaccine at 12 months of age |
| Menactra® at 9 Months and Menactra® + PCV at 12 Months | EXPERIMENTAL | Participants will receive Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age |
| MMRV + PCV at 12 Months | ACTIVE_COMPARATOR | Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age |
| Name | Type | Description |
|---|---|---|
| Meningococcal Polysaccharide Diphtheria Conjugate Vaccine | BIOLOGICAL | 0.5 mL dose, intramuscular (IM) |
| Measles, Mumps, Rubella and Varicella | BIOLOGICAL | 0.5 mL dose, SC |
Inclusion Criteria : * Healthy, as determined by medical history and physical examination * Aged 9 months (249 to 291 days) for Groups 1, 2, and 3 or aged 12 months (365 to 386 days) for Group 4 at the time of enrollment * The parent or legal guardian has signed and dated the Institutional Review B...
Measles, Mumps, Rubella and Varicella is a vaccine being studied for use in healthy volunteers and for meningococcal meningitis. It is a combination vaccine that includes components for measles, mumps, rubella, and varicella, and is being evaluated in clinical trials for its immunogenicity and safety.
Sanofi (ticker: SNY) is the developer of Measles, Mumps, Rubella and Varicella. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in pediatric populations.
Measles, Mumps, Rubella and Varicella is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The Phase 3 trials are completed, with one trial enrolling 1,664 participants and another enrolling 525 participants.
Measles, Mumps, Rubella and Varicella has been studied in two Phase 3 trials. NCT00422292 evaluated the vaccine's immunogenicity and safety when administered with Menactra in healthy toddlers in the United States and Puerto Rico. NCT03630705 assessed a quadrivalent meningococcal conjugate vaccine given with routine pediatric vaccines in healthy infants and toddlers in Russia and Mexico.
Yes, Measles, Mumps, Rubella and Varicella is also known as Measles, combinations with mumps and rubella, live attenuated. This alternative name reflects the vaccine's composition, which includes live attenuated components for measles, mumps, and rubella, along with varicella.